These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38439157)

  • 21. Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.
    Shendre A; Beasley TM; Brown TM; Hill CE; Arnett DK; Limdi NA
    Pharmacotherapy; 2014 Jun; 34(6):545-54. PubMed ID: 25032265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial.
    Verret L; Couturier J; Rozon A; Saudrais-Janecek S; St-Onge A; Nguyen A; Basmadjian A; Tremblay S; Brouillette D; de Denus S
    Pharmacotherapy; 2012 Oct; 32(10):871-9. PubMed ID: 23033226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Anderson JL; Li J; Rodriguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple B; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2019 Sep; 322(9):834-842. PubMed ID: 31479138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
    Kamphuisen PW; Lee AYY; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    J Thromb Haemost; 2018 Jun; 16(6):1069-1077. PubMed ID: 29573330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
    Leary E; Brilliant M; Peissig P; Griesbach S
    Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?
    Le Gal G; Carrier M; Tierney S; Majeed H; Rodger M; Wells PS
    J Thromb Haemost; 2010 Jan; 8(1):90-4. PubMed ID: 19874475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
    Schultz KT; Bungard TJ
    Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
    Ferder NS; Eby CS; Deych E; Harris JK; Ridker PM; Milligan PE; Goldhaber SZ; King CR; Giri T; McLeod HL; Glynn RJ; Gage BF
    J Thromb Haemost; 2010 Jan; 8(1):95-100. PubMed ID: 19874474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
    Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
    Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemorrhagic events lead to an increase in international normalized ratio in patients on warfarin.
    Perona S; Ford M; Rindone J
    J Pharm Pract; 2011 Oct; 24(5):494-7. PubMed ID: 22156711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal loading dose of warfarin for the initiation of oral anticoagulation.
    Mahtani KR; Heneghan CJ; Nunan D; Bankhead C; Keeling D; Ward AM; Harrison SE; Roberts NW; Hobbs FD; Perera R
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD008685. PubMed ID: 23235665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.
    Hylek EM; Chang YC; Skates SJ; Hughes RA; Singer DE
    Arch Intern Med; 2000 Jun; 160(11):1612-7. PubMed ID: 10847254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal loading dose for the initiation of warfarin: a systematic review.
    Heneghan C; Tyndel S; Bankhead C; Wan Y; Keeling D; Perera R; Ward A
    BMC Cardiovasc Disord; 2010 Apr; 10():18. PubMed ID: 20403189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.
    Shendre A; Brown TM; Liu N; Hill CE; Beasley TM; Nickerson DA; Limdi NA
    Pharmacotherapy; 2016 Mar; 36(3):263-72. PubMed ID: 26877068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled trial of genotype-based Coumadin initiation.
    Burmester JK; Berg RL; Yale SH; Rottscheit CM; Glurich IE; Schmelzer JR; Caldwell MD
    Genet Med; 2011 Jun; 13(6):509-18. PubMed ID: 21423021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.